North America was the largest region in the ophthalmology drugs market in 2017, accounting for around 31% of the total market. Read Report https://www.thebusinessresearchcompany.com/report/ophthalmology-drugs-global-market-report-2018

1. Ophthalmology Drugs
Global Market Report 2018
Including: Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological Drugs
Covering: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc,
Valeant Pharmaceuticals Intl Inc., Bayer AG
Feb 2018

2. Reasons to Purchase
• Outperform competitors using accurate up to date demand-side dynamics
information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the
drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high
quality data and analysis
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 3-5
working days of order.
Markets Covered: Antiglaucoma Drugs; Dry Eye Medication; Other Ophthalmological
Drugs
Companies Mentioned: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc, Valeant
Pharmaceuticals Intl Inc., Bayer AG
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and
Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America,
Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita,
Ophthalmology Drugs Indicators Comparison.
Data segmentations: Country and regional historic and forecast data, market share of
competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end
notes.
Scope

3. Ophthalmology Drugs Market
Characteristics
The ophthalmology drugs market covers drugs that are used in the treatment of
eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis,
retinal diseases, and macular degeneration. Some of the major ophthalmic drugs
include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.
The market numbers in this briefing cover pharmaceutical (drug) treatments and
do not cover biologic treatments for these conditions which are included in a
separate briefing. This market is further classified as follows –
Anti-glaucoma drugs are used for the treatment of glaucoma, a disease that
Dry Eye Medications include drugs to
Other Ophthalmological Drugs – These include drugs for
In this report market value is defined as the revenues organizations earn by selling
their goods and services within the specified market, based on the price at which
they sell. Only goods and services traded between entities are included.
The revenues for a specified geography are consumption values – that is, they are
revenues generated by organizations in the specified geography within the
specified market, irrespective of where they are produced.

4. Ophthalmology Drugs Market
Historic Growth
The global ophthalmology drugs market grew from $X billion in 2013 to $X billion
in 2017 at a compound annual growth rate (CAGR) of X%.
The chart and table below shows the year-on-year growth of the global
ophthalmology drugs market during 2013 – 2017.
Drivers of the Market:
Restraints on the Market:

5. Ophthalmology Drugs Market
Forecast Growth
The global ophthalmology drugs market is expected to grow from $XX billion in
2017 to $ 36.3 billion in 2021 at a compound annual growth rate (CAGR) of XX%.
This can be attributed to the expected rise in prevalence of eye conditions such as
age-related macular degeneration (AMD), diabetic retinopathy and glaucoma that
require ophthalmology drugs.
The chart and table below shows the year-on-year growth of the global
ophthalmology drugs market during 2017 - 2021.
Drivers of the Market:
Restraints on the Market:

6. Ophthalmology Drugs Market
Segmentation
The chart and table below shows the split of the ophthalmology drugs market in
2017.
The total market value for ophthalmology drugs was $X billion in 2017. The markets
that are covered include Antiglaucoma Drugs; Dry Eye Medication; Other
Ophthalmological Drugs.
Antiglaucoma Drugs was the X largest segment in the ophthalmology drugs market
with X% share of the market. The market value for the antiglaucoma drugs was $X
billion in 2017.
Dry Eye Medication made up around X% share of the market. The market value for
the dry eye medication was $X billion in 2017.

7. Ophthalmology Drugs Market
Regional And Country Analysis
The Asia Pacific was the largest region in the ophthalmology drugs market in 2017,
ophthalmology drugs for $X billion or X% market share.
North America was the x largest region ophthalmology drugs for $X billion or X%
market share.
Western Europe was the x largest region ophthalmology drugs for $X billion or X%
market share.

8. Ophthalmology Drugs Market
Competitive Landscape
The leading competitors in the global ophthalmology drugs market are Novartis AG,
F. Hoffmann-La Roche Ltd., Allergan Plc, Valeant Pharmaceuticals Intl Inc., Bayer
AG.
The chart and table below displays the percentage market share of the top players
in the ophthalmology drugs market industry.
Novartis AG generated revenues of $XX billion for the financial year 2016, an XX%
decrease from the previous year.
F. Hoffmann-La Roche Ltd. generated revenues of $XX billion for the financial year
2016, an XX% decrease from the previous year.
Allergan Plc. generated revenues of $XX billion for the financial year 2016, an XX%
increase from the previous year.
Valeant Pharmaceuticals Intl Inc. generated revenues of $XX billion for the
financial year 2016, an XX% increase from the previous year.

9. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX%
increase from the previous year.
Santen Pharmaceutical Co., Ltd. generated revenues of $XX billion for the
financial year 2016, an XX% increase from the previous year.
Gilead generated revenues of $XX billion for the financial year 2016, an XX%
decrease from the previous year.
Otsuka Pharmaceutical Co., Ltd. generated revenues of $XX billion for the
financial year 2016, an XX% decrease from the previous year.
Shire Plc. generated revenues of $XX billion for the financial year 2016.
Company Profile
Novartis AG
Overview
Novartis AG was the largest competitor in the ophthalmology drugs market
in 2017 with a XX% share of the market. Novartis is a multinational
pharmaceutical company that develops, manufacture and markets
healthcare products. The company was founded in 1970 and is
headquartered in Basel, Switzerland.
Products and Services
The company operates through the following divisions –
The Innovative Medicines division focuses on
The Alcon division focuses on the
The Sandoz division focuses on

10. Strategy
Novartis’ growth strategy is to focus on strengthening its ophthalmology
pipeline through acquisitions. In December 2016, the company acquired
pharmaceutical company Encore Vision, Inc. that develops treatment for
presbyopia, an ophthalmologic disorder. In addition, Novartis is
Financial Performance
Novartis’ Ophthalmology division, involved in ophthalmology drugs
manufacturing, generated revenues of $XX billion for the financial year
2016, a XX% decrease from the previous year. The company had a market
F. Hoffmann-La Roche Ltd.
Overview
Products and Services
Strategy
Financial Performance
Allergan Plc
Overview
Products and Services
Strategy
Financial Performance
Valeant Pharmaceuticals Intl Inc.
Overview
Products and Services
Strategy
Financial Performance
Bayer AG
Overview
Products and Services
Strategy
Financial Performance